Abstract: The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.

Abstract: The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.

Abstract: The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.

Abstract: The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.

Abstract: Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.

Abstract: A system for processing a plurality of tests or syntheses in parallel comprising a sample channel for moving samples into a microlaboratory array of a plurality of wells connected by one or more channels for the testing or synthesis of samples, a station for housing the array and an optical system comprising at least one light source and at least one light detector for measuring the samples in the array, and a means of electrically connecting said array to an apparatus capable of monitoring and controlling the flow of fluids into the array. Samples are loaded from a common loading channel into the array, processed in the wells and measurements taken by the optical system. The array can process many samples, or synthesize many compounds in parallel, reducing the time required for such processes.

Abstract: Macromolecular conjugates of a synthetic polypeptide having influenza virus antigenic properties are disclosed. These conjugates contain a polypeptide corresponding substantially to the 215-235 region of the matrix protein (M-protein) of influenza virus.

Abstract: Synthetic polypeptides having influenza virus antigenic properties are disclosed. These polypeptides correspond substantially to the 215 to 235 region of the matrix protein of influenza virus. Salts, derivatives, and conjugates of these polypeptides are disclosed as well as methods for using these materials for diagnostic and medical/veterinary purposes.

Abstract: An apparatus for simultaneously performing a multiplicity of synthesis reactions is disclosed. The synthesizer includes at least one reaction vessel having an access port and a synthesis compartment adjacent the access port. A closable exit channel with an exit port is adjacent the synthesis compartment. The apparatus also includes a base having a plurality of inlets, each of the inlets configured to receive the exit channel of the reaction vessel. A fluid outlet is present that is in communication with the plurality of inlets. A vacuum pump and vacuum line are connected to the fluid outlet for sucking excess reagents and by-products from the reaction vessel. The apparatus further includes a shaker for shaking the reaction vessel while synthesis is proceeding.

Abstract: A novel method of defining oligopeptides is provided for determining useful immunodominant sequences for use as vaccines for pathogens. The method involves identifying sequences by particular selection procedures and using such sequences with antigen-presenting cells and T-cells to demonstrate activation of the common histocompatibility antigens DQ and DR in humans and their analogs in other animals. The oligopeptides may then be used individually or in combination to produce safe and effective vaccines, where genes may be prepared encoding the oligopeptides and used for expression of the oligopeptides or combinations of the oligopeptides or the gene transformed into the appropriate host, e.g., B. pertussis, for use as a vaccine to the intact organism.

Abstract: Synthetic polypeptides having influenza virus antigenic properties are disclosed. These polypeptides correspond substantially to particular regions in the matrix protein of influenza virus. Salts, derivatives, and conjugates of these polypeptides are disclosed as well as methods for using these materials for diagnostic and medical/veterinary purposes.

Abstract: The present invention provides a stabilized potassium ion-selective membrane comprising lysine-substituted valinomycin covalently bound to a polymeric substrate. The membrane of the invention exhibits improved stability and is used either on ISEs or on solid-state coated wire or semiconductor devices.